Regeneron trades at 20x earnings with $16 billion in net cash
REGN Regeneron Pharmaceuticals Inc
$955.47 +0.45%
View chart & analysis → - 1Regeneron shares have risen more than 40% in one year.
- 2Trading at a price-to-earnings multiple of 20x, Regeneron may be the cheapest among large biotech companies.
- 3Regeneron's net cash of $16 billion is as of the end of the recent quarter.
So what's the key point?
Regeneron's stock price has risen more than 40% in a year. The company's stock price is quite low compared to its earnings.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.